This Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) provides $518,754 to Magee-Womens Research Institute And Foundation to develop an extended-release vaginal film that co-delivers a contraceptive monoclonal antibody (MAb) and antiviral MAbs against HIV and herpes simplex virus (HSV). The goal is to create a versatile, low-cost vaginal multipurpose prevention technology (MPT) that can provide contraception and protection against sexually transmitted infections for up to 7 days after a single application. The award period is from February 1, 2025 to January 31, 2026. If successful, this project will produce a lead prototype ER MPT film product that is positioned for advancement to clinical evaluation.
Generated 3/4/25, 7:52 AM